Literature DB >> 31925644

NLRC5: new cancer buster?

Feng Tang1,2, Yadi Xu3,4, Bing Zhao5,6.   

Abstract

Recent decades, there is significant progress in understanding the mechanisms of tumor progression and immune evasion. The newly discovered protein NLRC5 is demonstrated to participate in regulating cancer immune escape through enhancing MHC class I genes expression in certain tumors. Nevertheless, increasing evidence has revealed that NLRC5 is up-regulated in some other tumors and promote tumor development and progression. The purpose of this review is to describe the role of NLRC5 in tumors and discuss whether NLRC5 can be a potential target in cancer treatment.

Entities:  

Keywords:  Immunotherapy; NLRC5; Tumor

Mesh：

Substances：

Year:  2020        PMID： 31925644     DOI： 10.1007/s11033-020-05253-5

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN： 0301-4851            Impact factor:   2.316


  52 in total

1.  A role for the human nucleotide-binding domain, leucine-rich repeat-containing family member NLRC5 in antiviral responses.

Authors:  Andreas Neerincx; Katja Lautz; Maureen Menning; Elisabeth Kremmer; Paola Zigrino; Marianna Hösel; Hildegard Büning; Robert Schwarzenbacher; Thomas A Kufer
Journal:  J Biol Chem       Date:  2010-06-10       Impact factor: 5.157

2.  The nucleotide-binding domain of NLRC5 is critical for nuclear import and transactivation activity.

Authors:  Torsten B Meissner; Amy Li; Yuen-Joyce Liu; Etienne Gagnon; Koichi S Kobayashi
Journal:  Biochem Biophys Res Commun       Date:  2012-01-28       Impact factor: 3.575

Review 3.  Intracellular NOD-like receptors in host defense and disease.

Authors:  Thirumala-Devi Kanneganti; Mohamed Lamkanfi; Gabriel Núñez
Journal:  Immunity       Date:  2007-10       Impact factor: 31.745

4.  Screening for the pedal manifestations related to chemical abuse.

Authors:  A E Helfand; W C Anania; S L Chinkes; R C Rosen; P R Turner
Journal:  J Am Podiatr Med Assoc       Date:  1988-01

Review 5.  Expression regulation and function of NLRC5.

Authors:  Yikun Yao; Youcun Qian
Journal:  Protein Cell       Date:  2013-03-13       Impact factor: 14.870

6.  NLRC5 negatively regulates the NF-kappaB and type I interferon signaling pathways.

Authors:  Jun Cui; Liang Zhu; Xiaojun Xia; Helen Y Wang; Xavier Legras; Jun Hong; Jiabing Ji; Pingping Shen; Shu Zheng; Zhijian J Chen; Rong-Fu Wang
Journal:  Cell       Date:  2010-04-30       Impact factor: 41.582

7.  [Attempts at protecting an accidentally opened dental pulp].

Authors:  D Najzar-Fleger; L Pavelic
Journal:  Acta Stomatol Croat       Date:  1971

8.  Effect of mild heat treatment on the ATPase activity and proteolytic sensitivity of myosin subfragment-1.

Authors:  A Setton; A Muhlrad
Journal:  Arch Biochem Biophys       Date:  1984-12       Impact factor: 4.013

Review 9.  Regulation of immune pathways by the NOD-like receptor NLRC5.

Authors:  Mohamed Lamkanfi; Thirumala-Devi Kanneganti
Journal:  Immunobiology       Date:  2011-09-08       Impact factor: 3.144

10.  NLR family member NLRC5 is a transcriptional regulator of MHC class I genes.

Authors:  Torsten B Meissner; Amy Li; Amlan Biswas; Kyoung-Hee Lee; Yuen-Joyce Liu; Erkan Bayir; Dimitrios Iliopoulos; Peter J van den Elsen; Koichi S Kobayashi
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-16       Impact factor: 11.205
View more
  8 in total

1.  Dysregulation of long noncoding RNA MEG3 and NLRC5 expressions in patients with relapsing-remitting multiple sclerosis: is there any correlation?

Authors:  Shahram Torkamandi; Shima Bahrami; Tahereh Ghorashi; Mohammad Dehani; Hadi Bayat; Seyyed Mohamad Hoseini; Somaye Rezaei; Mohsen Soosanabadi
Journal:  Genes Immun       Date:  2021-11-15       Impact factor: 2.676

2.  Identification of Tumor Antigens and Immune Subtypes of Esophageal Squamous Cell Carcinoma for mRNA Vaccine Development.

Authors:  Tong Lu; Ran Xu; Cheng-Hao Wang; Jia-Ying Zhao; Bo Peng; Jun Wang; Lin-You Zhang
Journal:  Front Genet       Date:  2022-06-06       Impact factor: 4.772

3.  Thrombospondin-2 acts as a bridge between tumor extracellular matrix and immune infiltration in pancreatic and stomach adenocarcinomas: an integrative pan-cancer analysis.

Authors:  Xingchen Liao; Wei Wang; Baoping Yu; Shiyun Tan
Journal:  Cancer Cell Int       Date:  2022-06-14       Impact factor: 6.429

4.  Adult-type granulosa cell tumor of the ovary: a FOXL2-centric disease.

Authors:  Jessica A Pilsworth; Dawn R Cochrane; Samantha J Neilson; Bahar H Moussavi; Daniel Lai; Aslı D Munzur; Janine Senz; Yi Kan Wang; Sina Zareian; Ali Bashashati; Adele Wong; Jacqueline Keul; Annette Staebler; Hannah S van Meurs; Hugo M Horlings; Stefan Kommoss; Friedrich Kommoss; Esther Oliva; Anniina Em Färkkilä; Blake Gilks; David G Huntsman
Journal:  J Pathol Clin Res       Date:  2021-01-11

5.  Inhibition of NLRC5 attenuates the malignant growth and enhances the sensitivity of gastric cancer cells to 5-FU chemotherapy by blocking the carcinogenic effect of YY1.

Authors:  Shan Liang; Tingting Xiang; Shiyu Liu; Wei Xiang
Journal:  Exp Ther Med       Date:  2022-07-28       Impact factor: 2.751

6.  Clinical and Molecular Correlates of NLRC5 Expression in Patients With Melanoma.

Authors:  Lei Lv; Qinqin Wei; Zhiwen Wang; Yujia Zhao; Ni Chen; Qiyi Yi
Journal:  Front Bioeng Biotechnol       Date:  2021-07-09

Review 7.  NLRC5: A Potential Target for Central Nervous System Disorders.

Authors:  Lu Zhang; Cui Jiao; Lingjuan Liu; Aiping Wang; Li Tang; Yi Ren; Peng Huang; Jie Xu; Dingan Mao; Liqun Liu
Journal:  Front Immunol       Date:  2021-06-18       Impact factor: 7.561

8.  NFE2L2 Is a Potential Prognostic Biomarker and Is Correlated with Immune Infiltration in Brain Lower Grade Glioma: A Pan-Cancer Analysis.

Authors:  Qiang Ju; Xinmei Li; Heng Zhang; Songxia Yan; Ying Li; Yanjie Zhao
Journal:  Oxid Med Cell Longev       Date:  2020-10-09       Impact factor: 7.310
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.